Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Major depressive disorders Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
Obsessive-compulsive disorder Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
“Paroxetine is a potent and selective inhibitor of 5-hydroxytryptamine (5-HT, serotonin) uptake and its antidepressant action and efficacy in the treatment of obsessive-compulsive disorder (OCD), panic disorder, social anxiety disorder/social phobia, General Anxiety Disorder and Post-traumatic Stress Disorder are thought to be related to its specific inhibition of 5-HT uptake in brain neurones.”
“The elimination half-life is variable but is generally about one day. However, because of the reduction in plasma clearance which occurs on multiple dosing (non-linear kinetics: see Absorption ), 7-14 days are required for the achievement of steady state.”
Working under the parallel aged-care framework? Aged-care equivalent →
Panic disorder Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“The metabolism of paroxetine is accomplished in part by CYP2D6. Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment. At steady state, when CYP2D6 is essentially saturated, paroxetine clearance is governed by alternate P450 isoenzymes, which, unlike CYP2D6, are not saturable at clinical doses (as evidenced by linear pharmacokinetics in CYP2D6 deficient individuals).”